1 Ocak 2019 Dergi makalesi Açık Erişim

Farzani, Touraj Aligholipour; Foldes, Katalin; Hanifehnezhad, Alireza; Ilce, Burcu Yener; Dagalp, Seval Bilge; Khiabani, Neda Amirzadeh; Erguenay, Koray; Alkan, Feray; Karaoglu, Taner; Bodur, Hurrem; Ozkul, Aykut

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Farzani, Touraj Aligholipour</dc:creator>
  <dc:creator>Foldes, Katalin</dc:creator>
  <dc:creator>Hanifehnezhad, Alireza</dc:creator>
  <dc:creator>Ilce, Burcu Yener</dc:creator>
  <dc:creator>Dagalp, Seval Bilge</dc:creator>
  <dc:creator>Khiabani, Neda Amirzadeh</dc:creator>
  <dc:creator>Erguenay, Koray</dc:creator>
  <dc:creator>Alkan, Feray</dc:creator>
  <dc:creator>Karaoglu, Taner</dc:creator>
  <dc:creator>Bodur, Hurrem</dc:creator>
  <dc:creator>Ozkul, Aykut</dc:creator>
  <dc:date>2019-01-01</dc:date>
  <dc:description>Crimean-Congo hemorrhagic fever virus (CCHFV) is the causative agent of a tick-borne infection with a significant mortality rate of up to 40% in endemic areas, with evidence of geographical expansion. Due to a lack of effective therapeutics and control measures, the development of a protective CCHFV vaccine remains a crucial public health task. This paper describes, for the first time, a Bovine herpesvirus type 4 (BoHV-4)-based viral vector (BoHV4- increment TK-CCHFV-N) and its immunogenicity in BALB/c and protection potential in IFN alpha/beta/gamma R-/- mice models in comparison with two routinely used vaccine platforms, namely, Adenovirus type 5 and a DNA vector (pCDNA3.1 myc/His A), expressing the same antigen. All vaccine constructs successfully elicited significantly elevated cytokine levels and specific antibody responses in immunized BALB/c and IFN alpha/beta/gamma R-/- mice. However, despite highly specific antibody responses in both animal models, the antibodies produced were unable to neutralize the virus in vitro. In the challenge experiment, only the BoHV4- increment TK-CCHFV-N and Ad5-N constructs produced 100% protection against lethal doses of the CCHFV Ank-2 strain in IFN alpha/beta/gamma R-/- mice. The delivery platforms could not be compared due to similar protection rates in IFN alpha/beta/gamma R-/- mice. However, during the challenge experiment in the T cell and passive antibody transfer assay, BoHV4- increment TK-CCHFV-N was dominant, with a protection rate of 75% compared to others. In conclusion, vector-based CCHFV N protein expression constitutes an effective approach for vaccine development and BoHV-4 emerged as a strong alternative to previously used viral vectors.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/71641</dc:identifier>
  <dc:identifier>oai:zenodo.org:71641</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>VIRUSES-BASEL 11(3)</dc:source>
  <dc:title>Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFN alpha/beta/gamma R-/- Mice Models</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>